Latest Insider Transactions at Intercept Pharmaceuticals, Inc. (ICPT)
This section provides a real-time view of insider transactions for Intercept Pharmaceuticals, Inc. (ICPT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of INTERCEPT PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of INTERCEPT PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 01
2023
|
Jared Freedberg General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
771
-1.31%
|
$13,107
$17.07 P/Share
|
|
Mar 21
2023
|
Andrew Saik EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
909
-1.28%
|
$12,726
$14.19 P/Share
|
|
Mar 14
2023
|
M Michelle Berrey President, R&D and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,246
-1.49%
|
$18,690
$15.79 P/Share
|
|
Feb 14
2023
|
Linda M Richardson EVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
386
-0.88%
|
$8,106
$21.21 P/Share
|
|
Feb 01
2023
|
Jared Freedberg General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
918
-1.54%
|
$16,524
$18.76 P/Share
|
|
Jan 27
2023
|
Jared Freedberg General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
12,200
+16.97%
|
-
|
|
Jan 27
2023
|
Linda M Richardson EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,200
+21.83%
|
-
|
|
Jan 27
2023
|
Andrew Saik EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,700
+17.15%
|
-
|
|
Jan 27
2023
|
Rocco Venezia Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,800
+27.8%
|
-
|
|
Jan 27
2023
|
M Michelle Berrey President, R&D and CMO |
BUY
Grant, award, or other acquisition
|
Direct |
14,700
+14.91%
|
-
|
|
Jan 27
2023
|
Jerome Benedict Durso CEO |
BUY
Grant, award, or other acquisition
|
Direct |
50,400
+24.58%
|
-
|
|
Jan 27
2023
|
David A Ford Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,800
+21.19%
|
-
|
|
Dec 31
2022
|
M Michelle Berrey President, R&D and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
765
-1.09%
|
$9,180
$12.37 P/Share
|
|
Dec 31
2022
|
Jerome Benedict Durso CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,083
-6.36%
|
$84,996
$12.37 P/Share
|
|
Dec 31
2022
|
David A Ford Chief Human Resources Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,777
-6.25%
|
$21,324
$12.37 P/Share
|
|
Dec 31
2022
|
Jared Freedberg General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
718
-1.49%
|
$8,616
$12.37 P/Share
|
|
Dec 31
2022
|
Linda M Richardson EVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,600
-4.84%
|
$19,200
$12.37 P/Share
|
|
Dec 31
2022
|
Andrew Saik EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
718
-1.26%
|
$8,616
$12.37 P/Share
|
|
Dec 31
2022
|
Rocco Venezia Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
675
-4.13%
|
$8,100
$12.37 P/Share
|
|
Dec 21
2022
|
Andrew Saik EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
908
-1.57%
|
$11,804
$13.43 P/Share
|
|
Dec 14
2022
|
M Michelle Berrey President, R&D and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,246
-1.75%
|
$17,444
$14.94 P/Share
|
|
Nov 01
2022
|
Jared Freedberg General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
771
-1.57%
|
$11,565
$15.73 P/Share
|
|
Sep 21
2022
|
Andrew Saik EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
908
-1.54%
|
$12,712
$14.85 P/Share
|
|
Sep 14
2022
|
M Michelle Berrey President, R&D and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,246
-1.72%
|
$21,182
$17.14 P/Share
|
|
Sep 01
2022
|
Rocco Venezia Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
429
-2.56%
|
$7,722
$18.06 P/Share
|
|
Sep 01
2022
|
Linda M Richardson EVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
597
-1.77%
|
$10,746
$18.06 P/Share
|
|
Aug 15
2022
|
Linda M Richardson EVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
124
-0.37%
|
$2,232
$18.19 P/Share
|
|
Aug 01
2022
|
Jared Freedberg General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
771
-1.55%
|
$9,252
$12.21 P/Share
|
|
Jul 11
2022
|
Bryan Ball Chief Qual. Officer & SVP Ops. |
SELL
Payment of exercise price or tax liability
|
Direct |
436
-1.7%
|
$6,104
$14.57 P/Share
|
|
Jun 21
2022
|
Andrew Saik EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,632
-5.82%
|
$43,584
$12.48 P/Share
|
|
Jun 14
2022
|
M Michelle Berrey President, R&D and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,984
-6.44%
|
$59,808
$12.1 P/Share
|
|
May 25
2022
|
Dagmar Rosa Bjorkeson Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,737
+29.74%
|
-
|
|
May 25
2022
|
Keith Michael Gottesdiener Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,737
+23.84%
|
-
|
|
May 25
2022
|
Nancy Miller Rich Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,737
+25.75%
|
-
|
|
May 25
2022
|
Gino Santini Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,737
+24.65%
|
-
|
|
May 25
2022
|
Glenn Sblendorio Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,737
+24.81%
|
-
|
|
May 25
2022
|
Srinivas Akkaraju Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,737
+16.96%
|
-
|
|
May 25
2022
|
Luca Benatti Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,737
+23.29%
|
-
|
|
May 25
2022
|
Daniel Bradbury Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,737
+24.73%
|
-
|
|
May 25
2022
|
Fundaro Paolo Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,737
+17.77%
|
-
|
|
May 15
2022
|
Linda M Richardson EVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
124
-0.37%
|
$2,108
$17.88 P/Share
|
|
May 01
2022
|
Jared Freedberg General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
771
-1.53%
|
$11,565
$15.71 P/Share
|
|
Apr 11
2022
|
Bryan Ball Chief Qual. Officer & SVP Ops. |
SELL
Payment of exercise price or tax liability
|
Direct |
531
-2.03%
|
$9,027
$17.19 P/Share
|
|
Feb 15
2022
|
Linda M Richardson EVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
171
-0.5%
|
$2,565
$15.93 P/Share
|
|
Feb 14
2022
|
Linda M Richardson EVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
529
-1.53%
|
$7,406
$14.85 P/Share
|
|
Feb 12
2022
|
Gail Cawkwell SVP, Med Affairs, Safety & PV |
SELL
Payment of exercise price or tax liability
|
Direct |
320
-0.89%
|
$4,800
$15.8 P/Share
|
|
Feb 01
2022
|
Jared Freedberg General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
4,072
-7.46%
|
$65,152
$16.91 P/Share
|
|
Jan 27
2022
|
Bryan Ball Chief Qual. Officer & SVP Ops. |
BUY
Grant, award, or other acquisition
|
Direct |
3,600
+12.1%
|
-
|
|
Jan 27
2022
|
M Michelle Berrey President, R&D and CMO |
BUY
Grant, award, or other acquisition
|
Direct |
10,300
+11.74%
|
-
|
|
Jan 27
2022
|
Gail Cawkwell SVP, Med Affairs, Safety & PV |
BUY
Grant, award, or other acquisition
|
Direct |
6,600
+15.47%
|
-
|